These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11830342)

  • 21. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.
    Fried MW; Piratvisuth T; Lau GK; Marcellin P; Chow WC; Cooksley G; Luo KX; Paik SW; Liaw YF; Button P; Popescu M
    Hepatology; 2008 Feb; 47(2):428-34. PubMed ID: 18220290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of interferon-alpha treatment in children with hepatitis B e antigen-positive chronic hepatitis B virus infection: a meta-analysis of follow-up for six months to two years].
    Lin ZQ; Fang F; Guo ZF; Chen Q
    Zhonghua Er Ke Za Zhi; 2007 Aug; 45(8):592-8. PubMed ID: 18021533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection.
    Leemans WF; Flink HJ; Janssen HL; Niesters HG; Schalm SW; de Man RA
    J Hepatol; 2006 Mar; 44(3):507-11. PubMed ID: 16457904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Interferon therapy for chronic hepatitis B].
    Tang WL; Xie Q
    Zhonghua Gan Zang Bing Za Zhi; 2009 Oct; 17(10):726-9. PubMed ID: 19874685
    [No Abstract]   [Full Text] [Related]  

  • 26. [Low-levels of HBsAg quantification at 48-week in HBeAg-negative chronic hepatitis B patients are the advantageous population for HBsAg clearance].
    Yan YJ; Wang XX; Cao ZH; Lu JF; Jin Y; He ZM; Geng N; Ren S; Ma LN; Chen XY
    Zhonghua Gan Zang Bing Za Zhi; 2018 Nov; 26(11):813-818. PubMed ID: 30616314
    [No Abstract]   [Full Text] [Related]  

  • 27. Response to interferon-alpha in chronic hepatitis B patients with and without precore mutant strain and effects on HBsAg titers.
    Akhan SC; Yulugkural Z; Vahaboglu H
    Chemotherapy; 2007; 53(6):402-6. PubMed ID: 17934260
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Focus.
    Shouval D
    J Hepatol; 2013 Dec; 59(6):1151-2. PubMed ID: 24021425
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy and safety of peginterferon alpha-2a (40KD) in HBeAg-positive chronic hepatitis B patients.
    Caruntu FA; Streinu-Cercel A; Gheorghe LS; Grigorescu M; Sporea I; Stanciu C; Andronescu D; Voinea F; Diculescu M; Oproiu A; Voiosu R
    J Gastrointestin Liver Dis; 2009 Dec; 18(4):425-31. PubMed ID: 20076814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon.
    Boglione L; Cusato J; Allegra S; Esposito I; Patti F; Cariti G; Di Perri G; D'Avolio A
    Antiviral Res; 2014 Feb; 102():35-43. PubMed ID: 24316030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Models for predicting hepatitis B e antigen seroconversion in response to interferon-α in chronic hepatitis B patients.
    Wang CT; Zhang YF; Sun BH; Dai Y; Zhu HL; Xu YH; Lu MJ; Yang DL; Li X; Zhang ZH
    World J Gastroenterol; 2015 May; 21(18):5668-76. PubMed ID: 25987794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
    Takkenberg B; Terpstra V; Zaaijer H; Weegink C; Dijkgraaf M; Jansen P; Beld M; Reesink H
    J Gastroenterol Hepatol; 2011 Oct; 26(10):1527-35. PubMed ID: 21557773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study.
    Huang Z; Zhao Z; Zheng Y; Peng L; Lin C; Deng H; Gao Z
    J Viral Hepat; 2013 Apr; 20 Suppl 1():52-7. PubMed ID: 23458525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Study on the relationship between hepatitis B virus genotypes and the effect of polyethylene glycol-interferon-alpha therapy on HBeAg-positive chronic hepatitis B].
    Gao GS; Xu XZ; Hu YR; Yan HD
    Zhonghua Nei Ke Za Zhi; 2013 Dec; 52(12):1009-12. PubMed ID: 24503396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low HBeAg serum levels correlate with the presence of the double A1762T/G1764A core promoter mutation and a positive response to interferon in patients with chronic hepatitis B virus infection.
    Marrone A; Zampino R; Luongo G; Utili R; Karayiannis P; Ruggiero G
    Intervirology; 2003; 46(4):222-6. PubMed ID: 12931030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Study of the relapse of patients with chronic hepatitis B undergoing first and repeated recombinant interferon-alpha therapy during long-term follow up].
    Liu DL; Luo KX; Feng XR; Fu QX; Hou JL
    Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(26):1840-3. PubMed ID: 17922996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response to interferon-alpha 2a in patients with e antigen-negative chronic hepatitis B.
    Kako M; Kanai K; Aikawa T; Iwabuchi S; Takehira Y; Kawasaki T; Tsubouchi H; Hino K; Tsuda F; Okamoto H; Miyakawa Y; Mayumi M
    J Clin Gastroenterol; 1997 Sep; 25(2):440-5. PubMed ID: 9412946
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Influences of the genotypes of HBV and HBeAg regarding their response to PEG-IFN in chronic hepatitis B patients].
    Fan HB; Guo YB; Luo KX; Hou JL; Wang ZH; Zhang MX
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):488-90. PubMed ID: 16042879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The levels of HBsAg can predict the efficacy of peglated interferon-alpha 2a combined with adefovir dipivoxil, in HBeAg-positive chronic hepatitis B patients].
    Sun HX; Cao H; Zhang K; Yang XA; Li G; Xu QH
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Apr; 25(2):132-4. PubMed ID: 21863639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D.
    Erhardt A; Blondin D; Hauck K; Sagir A; Kohnle T; Heintges T; Häussinger D
    Gut; 2005 Jul; 54(7):1009-13. PubMed ID: 15951551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.